ArticleNeuro-oncology2021

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.

Bianca-Maria Marin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.